Aspirin-exacerbated respiratory disease and current treatment modalities (Q38931124)

7 September 2017

1 reference

title

Aspirin-exacerbated respiratory disease and current treatment modalities (English)

1 reference

7 September 2017

1 reference

1 reference

2

Nuray Bayar Muluk

1 reference

7 September 2017

4

Cemal Cingi

1 reference

7 September 2017

Emine Güven Sakalar

1

1 reference

7 September 2017

Murat Kar

series ordinal

3

1 reference

7 September 2017

publication date

18 August 2016

1 reference

European Archives of Oto-Rhino-Laryngology

7 September 2017

published in

1 reference

7 September 2017

volume

274

1 reference

7 September 2017

issue

3

1 reference

7 September 2017

page(s)

1291-1300

1 reference

Aspirin-Exacerbated Respiratory Disease: Evaluation and Management

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Upper airways in aspirin-exacerbated respiratory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Natural history and clinical features of aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Aspirin sensitivity and desensitization for asthma and sinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

The natural history and clinical characteristics of aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Aspirin-induced asthma: clinical aspects, pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Cysteinyl leukotrienes and their receptors; emerging concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Specific immunoglobulin E for staphylococcal enterotoxins in nasal polyps from patients with aspirin-intolerant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Superantigens and chronic rhinosinusitis: skewing of T-cell receptor V beta-distributions in polyp-derived CD4 and CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Control of arachidonate levels within inflammatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Intolerance to aspirin. Clinical studies and consideration of its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Update on the Management of Aspirin-Exacerbated Respiratory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Cross-reactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Profiling of Sputum Inflammatory Mediators in Asthma and Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Tailored therapy for severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Outcomes of modified endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Sodium salicylate sensitivity in an asthmatic patient with aspirin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

A systematic review of salicylates in foods: estimated daily intake of a Scottish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Salicylic acid in soups prepared from organically and non-organically grown vegetables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00405-016-4273-1

Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics

21 January 2018

1 reference

12 December 2020

EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

1 reference

12 December 2020

Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma

1 reference

12 December 2020

The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma

1 reference

12 December 2020

Pathogenic Mechanisms and In Vitro Diagnosis of AERD.

1 reference

12 December 2020

Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis.

1 reference

12 December 2020

Aspirin intolerance in asthma *1, *2Detection by oral challenge

1 reference

12 December 2020

Aspirin and salicylate in respiratory disease

1 reference

12 December 2020

Eicosanoids, aspirin-intolerance and the upper airways--current standards and recent improvements of the desensitization therapy

1 reference

12 December 2020

Clinical and pathologic perspectives on aspirin sensitivity and asthma

1 reference

12 December 2020

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

1 reference

12 December 2020

Recent studies on the chemical synthesis of eicosanoids

1 reference

12 December 2020

Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma☆☆☆★

1 reference

12 December 2020

Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis

1 reference

12 December 2020

European Position Paper on Rhinosinusitis and Nasal Polyps 2012.

1 reference

12 December 2020

The diagnosis of aspirin idiosyncrasy by analgesic challenge

1 reference

12 December 2020

10.1007/S00405-016-4273-1

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1052576760

0 references

1 reference